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Abstract
Background: A major problem in quantifying symptoms of schizophrenia is estab-
lishing a reliable distinction between enduring and dynamic aspects of psychopa-
thology. This is critical for accurate diagnosis, monitoring and evaluating treatment 
effects in both clinical practice and trials.
Materials and methods: We applied Generalizability Theory, a robust novel method 
to distinguish between dynamic and stable aspects of schizophrenia symptoms in the 
widely used Positive and Negative Symptom Scale (PANSS) using a longitudinal 
measurement design. The sample included 107 patients with chronic schizophrenia 
assessed using the PANSS at five time points over a 24-week period during a multi-
site clinical trial of N-Acetylcysteine as an add-on to maintenance medication for the 
treatment of chronic schizophrenia.
Results: The original PANSS and its three subscales demonstrated good reliability 
and generalizability of scores (G = 0.77-0.93) across sample population and occa-
sions making them suitable for assessment of psychosis risks and long-lasting change 
following a treatment, while subscales of the five-factor models appeared less reli-
able. The most enduring symptoms represented by the PANSS were poor attention, 
delusions, blunted affect and poor rapport. More dynamic symptoms with 40%-50% 
of variance explained by patient transient state including grandiosity, preoccupation, 
somatic concerns, guilt feeling and hallucinatory behaviour.
Conclusions: Identified dynamic symptoms are more amendable to change and 
should be the primary target of interventions aiming at effectively treating schizo-
phrenia. Separating out the dynamic symptoms would increase assay sensitivity in 
trials, reduce the signal to noise ratio and increase the potential to detect the effects 
of novel therapies in clinical trials.
K E Y W O R D S
clinical trial, generalizability theory, measurement, positive and negative syndrome scale, 
schizophrenia
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1 |  INTRODUCTION
A key issue for measuring psychopathological symptoms 
is the extent to which the underlying construct is stable or 
fluctuates over time.1 In schizophrenia, differentiation of 
enduring, as compared to responsive symptoms, has consid-
erable implications for understanding underpinning biopsy-
chosocial mechanisms, addressing problems associated with 
disease heterogeneity and improving health care.2-4 In par-
ticular, enduring negative symptoms may define a subgroup 
of patients differentiated on aetiology, life-impact of illness 
and poor response to medication.3,4 Poor understanding of 
aetiopathogenetic mechanisms of persistent negative symp-
toms limits the development of novel effective interventions.4 
Generalizability theory has been used to investigate enduring 
(trait) and dynamic (state; eg in response to environment or 
time point) symptoms in the context of mood disorders5 and 
psychological interventions (eg mindfulness)6 and might be 
applied to symptoms of schizophrenia.
Understanding differences between enduring and dynamic 
symptom patterns may help explain the discrepancy between 
observed changes in negative symptoms and the widely held 
belief amongst clinicians that negative symptoms are resis-
tant to treatment.7 Historically, positive symptoms (ie excess 
or distortion of normal functions, such as hallucinations or 
delusions) are found more amenable to change over time, 
while negative symptoms (ie diminution or loss of normal 
functions, such as affective flattening) are generally consid-
ered more enduring.8,9 However, Savill et al,7 reported a me-
ta-analysis that suggests negative symptoms do improve over 
time, across several treatment conditions, to a greater extent 
than previously thought. Nevertheless, another meta-analysis 
of 168 randomized placebo-control trials10 found that while 
most treatments reduced negative symptoms at follow-up 
relative to placebo, not to a clinically meaningful degree (ie 
as rated on the Clinical Global Impression Severity Scale).11 
Understanding which negative (and positive) symptoms are 
more amenable to change than others might help explain 
these discrepancies and would contribute to the development 
of scales to assess dynamic and fluctuating symptoms.
In addition to evaluate clinical meaningfulness in trials, 
it is essential to evaluate the extent to which the outcome 
measure is detecting true variability in symptoms.10 This 
involves evaluating potential sources of measurement error 
and requires a distinction between enduring and dynamic 
symptom patterns. Consequently, the psychological con-
struct of interest must be measured over multiple occasions. 
However, much of the research into the reliability of mea-
sures of psychological constructs has been conducted at sin-
gle time points, potentially missing important insights into 
the dynamic nature of psychological variables.12 For exam-
ple, in the context of personality (ie big five), repeated mea-
surement on multiple occasions suggests that up to 25% of 
the variability can be attributed to transient occasion effects, 
rather than differences in trait levels between persons.13
The Positive and Negative Syndrome Scale (PANSS) is 
a 30-item clinician-rated scale that assess the presence of 
positive symptoms, negative symptoms and general psy-
chopathology in people with schizophrenia.14 The PANSS 
is widely used as an outcome measure in clinical trials and 
generally has good reliability and validity. However, internal 
consistency of positive and general subscales are ‘modest’ 
and test-retest reliability ranged between 0.60 to 0.80 at sub-
scale level.14,15 This is of particular relevance to clinical trials 
where clinical measures must be sensitive to true change in 
symptoms over time. Identification of these patterns will bet-
ter identify clusters of individuals with specific patterns of 
schizophrenia symptoms from the general population.16
The reporting of composite subscale scores on the PANSS 
rather than individual item scores further decreases the abil-
ity to understand variation in individual symptoms over time. 
For example, some treatment studies select either the nega-
tive or positive subscale to identify changes in the symptoms 
of interest.17 This could lead to construct underrepresentation 
as the PANSS general subscale includes several possible neg-
ative symptoms and positive symptoms.14 This complexity 
increases with different factor structures of the PANSS which 
have been reported, such as a five-factor solution.18
Establishing the true reliability of a measure requires a 
distinction between stable and dynamic symptom patterns, 
which is only possible using repeated measures.6 For exam-
ple, Vangeneugden et al19 examined data from five random-
ized controlled trials (RCTs) across 18 countries and found 
that test-retest reliability was low and measurement error 
higher for patients with high scores on the PANSS negative 
symptoms subscale. Consequently, measurement error atten-
uates the ability to distinguish true change in symptoms from 
extraneous factors.19
The test-retest reliability coefficient is commonly used to 
evaluate consistency in scoring on psychological measures 
over two occasions. Test-retest reliability does not account 
for multiple sources of error that may affect the observed 
score on a testing occasion, such as interactions between per-
son, item and occasion.6 Vispoel et al12 demonstrated that re-
liability coefficients may be overinflated by as much as 24%, 
as single-occasion reliability coefficients do not account for 
transient error (eg occasion effects such as fatigue), whereas 
test-retest coefficients do not account for specific factor error 
(eg idiosyncratic responding due to error caused by items un-
related to the construct of interest).
Generalizability or G Theory is a sound method for evalu-
ating specific sources of measurement error in clinical trials.19 
While classical test theory assumes that an observation is a 
combination of an individual's true score and random measure-
ment error, G Theory uses analysis of variance (ANOVA) to 
calculate precise estimates for the error variance due to each 
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important measurement facet.20 Facet refers to any distinct el-
ement that the researcher theorizes might influence variance 
and error in test scores. For example, facets may be the persons 
tested (P), the test items (I) and the testing occasion (O). CTT 
restricts analysis of reliability and error variance to a single el-
ement such as the test items (Cronbach's alpha), the occasion 
(test-retest) or the rater (inter-rater) and does not allow for si-
multaneous evaluation of true score estimates. Importantly, G 
Theory also calculates separate variance components for the in-
teractions between facets (eg Person x Occasion). In G Theory 
terms, the variance associated with participants or persons is 
considered the central concern and is known as the differentia-
tion facet with other facets (eg items, occasion, rater) viewed as 
sources of measurement error.
Applying G Theory involves two stages: G-study and the 
D-study. The G-study involves a factorial ANOVA corrected 
for the type of sampling involved (ie random, fixed or mixed) 
and estimates a G-coefficient reflecting generalizability of the 
test scores across persons and situations. Bloch and Norman 
(p. 968)20 describe the G-coefficient as the ratio of ‘signal’ to 
‘noise’ or ‘true variance’ to ‘true + error variance’. The D-study, 
or Decision-study, allows the researcher to estimate the impact 
on reliability of variations in different facets such as increasing 
the number of participants or the number of items in a scale, 
and hence decide on the appropriate measurement protocols.
Only a few studies have applied G Theory to investigate the 
psychometric properties of the PANSS, and none distinguished 
between dynamic and stable symptom patterns using a longitu-
dinal (repeated measures) design. Vangeneugden et al19 argued 
that G Theory represents a powerful psychometric approach 
that has particular potential for clinical trials and demonstrated 
this in a G Theory study of the PANSS used across different 
countries. Khan et al21 applied G Theory to data from a failed 
clinical trial to determine the major sources of unreliability 
(Patient, Rater, Occasion) and concluded that the major source 
of variability in scores was Rater followed by Rater x Occasion. 
Being able to parse stable and dynamic symptoms may allow 
the development of a dynamic subscale which might increase 
assay sensitivity and increase the likelihood of detecting be-
tween-group change in trials of novel therapies for schizophre-
nia. In the present study, we apply G Theory to identify stable 
and dynamic symptom progression within the context of a clin-
ical trial involving a cohort of patients diagnosed with schizo-
phrenia to evaluate the psychometric properties of the PANSS, 
its subscales and individual items.
2 |  METHODS
2.1 | Participants
Participants were 107 patients with a longstanding diagnosis 
of schizophrenia (mean duration of illness, 12.2 ± 8.9 years) 
aged between 18 and 65 years, and randomized to N-acetyl 
cysteine (NAC, n = 54) or placebo (n = 53) in a controlled 
trial that was reported by Berk et al22 and approved by the 
authors institutional ethics committee. This subsample satis-
fies requirements for reliability study in medical research23 
and was selected from a larger sample of 140 patients based 
on the availability of complete PANSS data from five sepa-
rate assessments collected at two-week intervals (Baseline, 
week 2, week 4, week 6 and week 8). Exclusion of 33 par-
ticipants with missing data was assumed as random because 
missing data were completely at random. We have also esti-
mated if the reduced sample was statistically different from 
the full sample using Monte Carlo stimulation that indicated 
no significant difference with upper bound overlapping P-
value cut-off point of .05 [99%CI; 0.04, 0.05]. Patients were 
required to have residual symptoms, as defined by a baseline 
PANSS Total score of ≥55 or at least two of the positive 
and/or negative items being ≥3 despite maintenance treat-
ment with atypical antipsychotic medications. The inclusion 
criteria were selected so that participants had current symp-
toms (mildly ill +) based on the literature of trials.23 Both the 
placebo and NAC groups exhibited significant baseline-week 
8 reductions in the PANSS Positive, Negative, General and 
Total scores. There were no significant treatment group dif-
ferences for baseline-week 8 change in all PANSS measures 
(P > .05), and these groups were therefore combined for the 
present analysis.
2.2 | Measures
The PANSS14 is a 30-item rating scale with seven positive 
symptom items (eg delusions, hostility), seven negative 
symptom items (eg blunted affect, poor rapport) and 16 rep-
resenting general psychopathology (eg anxiety, depression). 
Each item or symptom is rated on a seven-point scale repre-
senting increasing psychopathology from 1 (absent) to 7 (ex-
treme). Scores are obtained for positive symptoms, negative 
symptoms, general psychopathology and a composite score. 
Raters were either clinical psychologists or medical practi-
tioners who had undergone training on the PANSS.
2.3 | Generalizability analysis
Generalizability analyses were conducted following the 
guidelines described elsewhere (Gardinet et al, 2009) and 
employed EduG 6.1-e software.24 Both the G (generalizabil-
ity) and D (decision) studies used a persons (P), by item (I), 
by occasion (O) random effects design expressed as P × O 
× I, where the I facet is fixed and the P and O facets are 
infinite Table 1. This two-facet design considered persons 
as the object of measurement, defined as the differentiation 
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facet and not a source of error, and items and occasions as 
the instrumentation facets (Figure 1).25 Error variance due 
to person-occasion interaction in a scale score can be in-
terpreted as reflecting a dynamic component or individual 
state.6
Variance components for each facet and their interactions 
were computed based on traditional ANOVA estimates using 
equations introduced by Brennan.26 Whimbey’s correction 
was applied to traditional ANOVA estimates that consider 
finite facets, such as items, that are not derived from infinite 
populations.25 Whimbey’s correction has no effect on ran-
dom facets (eg persons) and is expressed as ((N(f)−1)/N(f)), 
where N(f) is the population size of the f facet in the G-study 
design. The unique contribution of each facet to the total vari-
ance of universe scores was estimated using generalizability 
analysis and included relative and absolute error variance 
and G-coefficients for the differentiation facet (persons). 
The relative G-coefficient (Gr) is commonly expressed as ρ2, 
ϖ2 only considers variance directly related to the object of 
measurement. The absolute G-coefficient (Ga) is equivalent 
to Phi (Φ) and accounts for other variance sources (eg item x 
occasion interaction) that may influence an absolute measure 
indirectly.25 To measure scale/item ability to assess dynamic 
and enduring symptoms, a state component index (SCI) and 
trait component index (TCI) were computed respectively 
using formulas developed by Medvedev et al6 to reflect the 
proportion of variance attributed to dynamic and enduring 
aspects in a measure. The D-study investigated properties of 
individual items representing specific symptoms by reducing 
and varying facet designs aimed at optimizing measurement. 
Reporting of the study conforms to broad EQUATOR guide-
lines (Simera et al. January 2010 issue of EJCI).27
3 |  RESULTS
Descriptive statistics were computed for the five sepa-
rate PANSS assessments with the current sample and are 
presented in Table  2. The total PANSS and Negative and 
General symptom subscales displayed good internal consist-
ency across all five assessment points, ranging from 0.77 to 
0.89. Slightly lower but acceptable values (0.70-0.74) were 
observed for the Positive symptoms PANSS subscale. There 
was a statistically significant decrease in positive, general 
and overall symptoms at all assessment points compared to 
baseline.
3.1 | G-Study
Results of the G-Study analysis of the PANSS total scale, 3- 
and 5-factor models subscales are presented in Table 3. The 
total PANSS scale demonstrated acceptable generalizability 
of scores across occasions and sample population (Gr = 0.93/
Ga = 0.77), with a low proportion of variance attributed to 
dynamic fluctuations (SCI  =  0.13). The PANSS Positive, 
Negative and General Symptoms subscales showed slightly 
lower but still acceptable generalizability of scores across 
persons and occasions (Gr = 0.77-0.84; Ga = 0.72/0.74). All 
Persons (P) Person universe score p (averaged deviation from grand mean over 
items and occasions)
Items (I) Item effect i (averaged deviation from the grand mean over persons 
and occasions)
Occasions (O) Occasion effect o (averaged deviation from grand mean over 
persons and items)
P x I Effect of interaction between person p and item i averaged over 
occasions
P x O Effect of interaction between person p and occasion o averaged 
over items
I x O Effect of interaction between item i and occasion o
P x I x O, e Effect of interaction between person p, item i and occasion o, 
containing a random error e
T A B L E  1  Components definitions for 
two-facet Generalizability analysis person x 
item x occasion (P x I x O)
F I G U R E  1  Venn Diagram of Two-Facet Design (P x I x O)
   | 5 of 8MEDVEDEV Et al.
subscales of the 5-factor model appeared less reliable with 
both Gr and Ga below 0.70 bench mark.
3.2 | D-Study
The D-study aimed to identify the PANAS items that are 
sensitive to dynamic changes. Table  4 includes variance 
components of person (enduring symptoms), person x oc-
casion interaction (dynamic symptoms), and SCI values to 
determine items reflecting dynamic symptoms. SCI values 
ranged from 0.27 to 0.50 with a mean of 0.38 indicating that 
the majority of variance in the symptoms is explained by 
enduring patterns. There are five items reflecting the most 
stable symptoms with SCI ≤0.30 including poor attention, 
blunted affect, delusions, poor rapport, and mannerisms 
T A B L E  2  Means, standard deviation (SD), Cronbach's alpha and test-retest coefficients for the PANSS subscales and the total scale 
(n = 107 × 5 occasions)
Scale/Assessment Baseline 2 Weeks 4 Weeks 6 Weeks 8 Weeks
PANSS Positive
Mean (SD) 15.76 (5.28) 14.96* (5.08) 14.47** (5.38) 14.15**(5.29) 13.78**(5.18)
Cronbach's alpha 0.70 0.70 0.73 0.74 0.72
Test-retest (r)a -- 0.87 0.79 0.78 0.79
PANSS Negative
Mean (SD) 15.87 (6.13) 15.71 (6.19) 15.42 (6.17) 15.10* (6.03) 14.83** (6.10)
Cronbach's alpha 0.81 0.84 0.84 0.86 0.86
Test-retest (r)a -- 0.83 0.81 0.81 0.77
PANSS General
Mean (SD) 31.86 (8.23) 30.05**(8.30) 28.93** (8.00) 28.56**(8.69) 28.08**(8.30)
Cronbach's alpha 0.77 0.8 0.79 0.82 0.81
Test-retest (r)a -- 0.84 0.76 0.79 0.75
PANSS Total
Mean (SD) 63.49 (15.60) 60.72**(15.95) 58.82** (15.87) 57.81**(16.30) 56.69**(16.03)
Cronbach's alpha 0.86 0.88 0.88 0.89 0.89
Test-retest (r)a -- 0.86 0.82 0.81 0.78
Note: Mean difference is significant compared to the baseline.
aTest-retest bivariate correlations between assessment and the baseline. 
*P < .05. 
**P < .01. 
T A B L E  3  G-study estimates of variance components1
Scale/Subscale P I O PxI PxO IxO PxIxO G-r G-a SCI
PANSS Total 0.07 <0.00 0.02 <0.00 0.01 <0.00 <0.00 0.93 0.77 0.13
Positive Symptoms 0.18 <0.00 0.01 0.02 <0.00 <0.00 0.02 0.80 0.74 <0.00
Negative Symptoms 0.17 <0.00 0.01 0.03 <0.00 <0.00 0.02 0.77 0.72 <0.00
General Symptoms 0.09 <0.00 0.01 0.01 0.01 <0.00 0.01 0.84 0.74 0.10
5-Factor Model
Positive Symptoms 0.10 <0.00 0.02 0.03 0.01 0.01 0.03 0.65 0.57 0.09
Negative Symptoms 0.12 <0.00 0.01 0.04 <0.00 0.01 0.03 0.65 0.60 <0.00
Disorganization 0.08 <0.00 0.02 0.02 <0.00 <0.00 0.02 0.66 0.57 <0.00
Excitement 0.02 <0.00 0.02 0.07 0.01 <0.00 0.00 0.15 0.12 0.33
Emotional Distress 0.10 <0.00 0.00 0.04 <0.00 0.01 0.04 0.57 0.52 <0.00
1Differentiation variance component of person (P); Absolute error variance of item (I), occasion (O), interaction between person and item (PxI), person and occasion 
(PxO), item and occasion (IxO) and person, item and occasion (PxIxO); Relative G-coefficient (Gr); Absolute G-coefficient (Ga); and State Component Index (SCI) 
for P x O x I design including the PANSS total, 3SCI= (n = 107). 
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and posturing. However, there are also nine items re-
flecting the most dynamic symptoms with larger propor-
tion of state-related variance (SCI  =  40-50) including: 
hallucinatory behaviour, guilt feeling, somatic concern, 
preoccupation, grandiosity, disturbance of volition, motor 
retardation, uncooperativeness and lack of judgement and 
insight. Attempts to increase the scale sensitivity to tem-
poral changes by analysing various combinations of indi-
vidual items that are the most sensitive to dynamic change 
with SCI above the mean of 0.38 were unsuccessful due 
to larger proportion of trait-related (person) variance (eg 
SCI < 0.30).
4 |  DISCUSSION
The present study applied G Theory to evaluate reliability and 
quantify differences between dynamic and enduring symptom 
patterns in the PANSS within the context of a clinical trial 
involving a cohort of patients diagnosed with schizophrenia. 
Overall, the PANSS total scale demonstrated acceptable reli-
ability and was superior in performance when compared to 
the individual subscales. The total PANSS score reflected 
enduring symptoms to a greater, and dynamic symptoms to 
a lesser, extent and was not affected by any other measure-
ment error. The three individual PANSS subscales Positive 
Symptoms, Negative Symptoms and General Symptoms 
showed acceptable reliability and generalizability of scores 
across occasions and population of the sample. However, 
evaluation of the five-factor structure of the PANSS18 re-
vealed that all subscales had low reliability below widely the 
accepted 0.70 benchmark meaning that measurement error 
exceeded 30% for these subscales20 and consequently the use 
of a five-factor solution is not supported.
The current study distinguished between stable and more 
dynamic symptoms of schizophrenia using G Theory. The 
symptoms operationalized by the PANSS were overall more 
enduring, and the most stable symptoms included symptoms 
located on the general scale such as poor attention and man-
nerisms and posturing; symptoms on the positive scale of de-
lusions; and symptoms on the negative scale of blunted affect 
and poor rapport. However, the most dynamic symptoms on 
the positive scale were identified such as hallucinatory be-
haviour and grandiosity as well as symptoms on the general 
scale including guilt feeling, somatic concern, preoccupation, 
disturbance of volition, motor retardation, uncooperativeness 
and lack of judgement and insight.
It is notable that both the placebo and NAC groups exhib-
ited significant baseline-week 8 reductions in PANSS Total, 
Positive, General scores, but neither group exhibited signif-
icant reductions in PANSS Negative scores. While negative 
symptoms were generally stable, if symptoms at the subscale 
level were solely reported, then important dynamic changes 
occurring would be overlooked. For example, some symp-
toms on the negative subscale were dynamic, as were negative 
symptoms located on the general subscale (Motor retardation 
T A B L E  4  Variance components and the SCI for the individual 
PANSS items1
Items Symptoms/Variance P PO SCIc
G11 Poor attention 0.61 0.22 0.27
N1 Blunted affect 0.45 0.18 0.29
P1 Delusions 0.53 0.21 0.29
N3 Poor rapport 0.39 0.16 0.29
G5 Mannerisms and 
posturing
0.53 0.23 0.30
N6 Lack of spontaneity 
and flow
0.52 0.23 0.31
G16 Active social 
avoidance
0.33 0.16 0.33
N7 Stereotyped thinking 0.40 0.20 0.33
P4 Excitement 0.37 0.19 0.34






P7 Hostility 0.43 0.24 0.36
G10 Disorientation 0.29 0.17 0.37
G9 Unusual thought 
content
0.22 0.13 0.37






N2 Emotional withdrawal 0.38 0.24 0.39
G4 Tension 0.38 0.24 0.39
G6 Depression 0.38 0.24 0.39
G2 Anxiety 0.30 0.19 0.39
G14 Poor impulse control 0.28 0.18 0.39
G12 Lack judgement and 
insight
0.32 0.21 0.40
G8 Uncooperativeness 0.27 0.18 0.40
G7 Motor retardation 0.30 0.23 0.43
G13 Disturbance of 
volition
0.33 0.26 0.44
P5 Grandiosity 0.16 0.13 0.45
G15 Preoccupation 0.17 0.14 0.45
G1 Somatic concern 0.27 0.24 0.47




1Differentiation variance of person (P); Absolute error variance of person and 
occasion interaction (P x O); and the State Component Index (SCI). 
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and Disturbance of volition). While the PANSS and its sub-
scale scores can be used to evaluate the overall symptomatic 
change, individual item scores may be more useful than the 
scale and subscales scores to monitor more dynamic or en-
during symptoms as evaluated in Table 3. Examining individ-
ual symptom patterns as opposed to subscale and total scores 
enables valuable detailed evaluation of symptom patterns and 
response to treatment, yet has not been widely reported in 
schizophrenia research.
Although G Theory has previously been applied to the 
PANSS,20 no studies to date have focused on distinguishing 
between dynamic and enduring symptoms using an exten-
sive longitudinal measurement design over five time points. 
Establishment of which symptoms are most stable and which 
are relatively dynamic needs further exploration. While 
blunted affect and poor rapport were observed to be stable in 
the present study, Fusar-Poli et al10 observed global changes 
in negative symptoms over time. However, they used the tra-
ditional CTT methodology that is unable to separate clearly 
between variance due to change at the group level from vari-
ability of individual items reflecting symptoms at individ-
ual level while controlling for person variance.5 Therefore, 
Fusar-Poli et al10 findings of dynamic negative symptoms 
may illustrate the ability of negative items to reflect change 
at group level, but a poorer ability to reflect individual 
change accounting for unwanted error variance. In the pres-
ent study using more robust G Theory method, both stable 
and dynamic symptoms were found on the positive and gen-
eral subscales, which is not consistent with prior research 
based on CTT method and indicating that positive symptoms 
are overall more dynamic.9 This inconsistency is likely at-
tributed to limitations of CTT and highlights the needs for 
further replication these findings using G Theory with dif-
ferent sample varying of symptoms severity. Furthermore, it 
highlights the importance of evaluating individual item level 
change in symptoms rather than scale and subscales scores.
There are a number of potential limitations to the present 
study. Although combining placebo and treatment groups 
may confound interpretation of stable vs dynamic features in 
the context of treatment, the inclusion of a variety of symp-
tom levels was advantageous. Of note, baseline to week eight 
change for all PANSS measures did not differ significantly 
between groups, and the present analysis does identify stable 
vs dynamic symptom domains within the context of a clini-
cal trial. Second, patients in this study were treated with an 
atypical antipsychotic medication, which may differentially 
modify PANSS symptoms. N-acetyl cysteine is particularly 
likely to affect glutamate receptors and may be expected to 
have a greater effect on reality distortion and thought dis-
order symptoms. Therefore, assessment of medication-naive 
subjects, either at the initial onset of psychosis or subjects 
at ultra-high risk for developing schizophrenia, would repre-
sent an important extension of G theory and enable further 
exploration of stable and dynamic symptoms longitudinally. 
We also excluded 33 participants with missing data from 
the study sample that could potentially represent a selection 
bias. However, missing data were completely at random sug-
gesting random selection of participants for the study was 
assumed and there was no evidence that the reduced sample 
was statistically different from the full sample.
The results of this study inform future studies to develop 
an instrument for distinct and reliable measurement of dy-
namic and enduring schizophrenia symptoms. The current in-
vestigation of the PANSS provides a methodological pathway 
for the development of such instruments that would enhance 
clinical care by permitting accurate monitoring of patients 
symptoms over time using two mechanisms: first, by applying 
a dynamic symptoms scale to evaluate individual symptom 
change, and second, by assessing the overall psychopathol-
ogy level by simultaneously applying an enduring symptoms 
measure. This is particularly useful with adolescent popula-
tions for differential diagnosis between schizophrenia and the 
paranoid and dissociative symptoms associated with border-
line personality disorder,28 and to identify those at clinical 
high risk to develop psychosis.29
5 |  CONCLUSION
The present study highlights the value of G Theory for quan-
tifying stable and dynamic symptoms using the PANSS 
within the context of a clinical trial. The majority of symp-
toms represented by the PANSS were stable with the most 
enduring being poor attention, delusions, blunted affect and 
poor rapport. However, there are also more dynamic symp-
toms with 40%-50% of variance explained by the patients’ 
transient state including grandiosity, preoccupation, somatic 
concerns, guilt feeling and hallucinatory behaviour. These 
dynamic symptoms are more amendable, which makes them 
the primary target of interventions aiming to effectively treat 
schizophrenia.
The PANSS and its three subscales demonstrated accept-
able reliability and generalizability in measuring stable and 
dynamic symptoms of schizophrenia. The use of subscales 
within the 5-factors model of PANSS was not supported in 
this study and should be treated cautiously in other clinical 
trial contexts. Additional G Theory analyses of the PANSS 
are warranted using prodromal and medication-naive patients 
in a naturalistic setting to identify stable vs dynamic features 
associated with the progression of schizophrenia.
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